Skip to main content


Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Fig. 6

Representation of potentiated anticancer activity by PARP inhibitor combined with WEE1/PLK1 dual inhibitor against GC. PARP inhibitors prevent repairs of SSB that convert into DSB in the context of functional HR, which limits efficacy of PARP inhibitors against GC. In the presence of WEE1/PLK1 dual inhibitors, HR can be impaired and DNA damage checkpoint be inactivated to promote lethality of GC cells subjected to PARP inhibitors

Back to article page